Fibroheal Woundcare, a medical device startup that aims at providing solutions for wound care, recently closed a Rs 6.3 crore pre-Series A round. The round involved current promoters and a set of fresh investors from a different circle inclusive of prominent surgeons, clinicians, and bankers. However, there is incremental fundraising of Rs 10 crore from new and existing investors that has also been made.
Commitment to Growth and Innovation
The R&D and new product development, along with the growth of its employee base and its marketing framework, would be the uses for the funds for Fibroheal.
It is for this reason that the company, which produces silk protein-based medical devices, seeks to extend these investments to establish itself more firmly in this burgeoning field of wound care. KK Narayanan, a prominent figure in the round, emphasized the Fibroheal prospects, asserting that it employs natural silk technology and has a great team to back it up.
Expansion and Market Presence
Fibroheal offers several foams, meshes, and powders for the treatment of acute, chronic, traumatic, post-operative, and non-healing wounds like bedsores or C-section wounds.
Currently, its products are already approved to be used in more than 500 hospitals in India, and now they operate in 19 states. Moreover, Fibroheal has expanded its capability to the e-commerce platform as a way of selling its products.
Market Expansion in the Indian Wound Care Industry
The fundraising is in line with the rising need for wound care products in India owing to the burgeoning incidence of chronic illnesses, spending on health, and knowledge. In a report published in 2024 by Mordor Intelligence, the wound care segment is growing at a high rate and holds great potential in the market for companies like Fibroheal.
Thus, based on its strong roots, dedicated management team, and unique offerings, Fibroheal has great potential to challenge the wound care market.
